| HOME | MEETINGS | MEMBERSHIP | EXHIBITORS | AWARDS | INFO | NEWS | ABOUT US | CONTACT | SIGN IN |
ensuring knowledge, enhancing quality
A 'not-for-profit' organisation,
run for pharmaceutical analysts by pharmaceutical analysts
JPAG - PAST MEETINGS
RETURN TO MEETINGS
Thursday 10th October 2019
Mutagenic Impurities
Royal Society of Chemistry, London
This one-day joint symposium with the RSC Toxicology group will address issues and challenges associated with the implementation of ICH M7 guideline.
It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance relating to:
* Regulatory and pharmacopeial interpretation
* Valsartan update
* Purging update from Mirabilis consortium
* State of the art approaches to analysis of MIs
* How do I present my MI data in a regulatory submission?
This is an excellent opportunity to learn from expert speakers who have been actively involved in the development of the guidance on these key topics.
Speakers:
Dr Michael Burns - Lhasa
Mark Harrison - AstraZeneca
Dr George Johnson - Swansea University
Richard Jones - GlaxoSmithKline
Dr Henry Stemplewski - MHRA
Dr Andrew Teasdale - AstraZeneca
Dr Mike Urquhart - GlaxoSmithKline
Mutagenic Impurities
Royal Society of Chemistry, London
This one-day joint symposium with the RSC Toxicology group will address issues and challenges associated with the implementation of ICH M7 guideline.
It will provide an excellent opportunity for dialogue, discussion and debate with speakers - several of whom have been actively involved in shaping the guidance - and the peer group in an open forum.
Delegates will be able to understand, interpret and translate into day-to-day practice the guidance relating to:
* Regulatory and pharmacopeial interpretation
* Valsartan update
* Purging update from Mirabilis consortium
* State of the art approaches to analysis of MIs
* How do I present my MI data in a regulatory submission?
This is an excellent opportunity to learn from expert speakers who have been actively involved in the development of the guidance on these key topics.
Speakers:
Dr Michael Burns - Lhasa
Mark Harrison - AstraZeneca
Dr George Johnson - Swansea University
Richard Jones - GlaxoSmithKline
Dr Henry Stemplewski - MHRA
Dr Andrew Teasdale - AstraZeneca
Dr Mike Urquhart - GlaxoSmithKline
GET THE REPORT FOR THIS EVENT?
We will send it to you.
We will send it to you.
RETURN TO MEETINGS
WANT TO SEE MORE?
You will have access to materials for meetings that you have attended.
You will need to Sign In to activate access to your additional options.
Once Signed in, click on RESOURCES and look under MY PAST MEETINGS.
You will have access to materials for meetings that you have attended.
You will need to Sign In to activate access to your additional options.
Once Signed in, click on RESOURCES and look under MY PAST MEETINGS.
PAST MEETINGS
Symposium - October 2011
Delegates at a symposium held at the Royal Pharmaceutical Society
| Call us: | CONTACT US | Follow us: |     | Terms and Conditions Privacy Statement |
| Joint Pharmaceutical Analysis Group 2024 Website © and by Delta Consultancy Services |
|